<p>Regeneron 的高管对 fianlimab + Libtayo 的潜力持乐观态度；当研究未能产生预期结果时，股票开盘下跌超过 10%。</p>
<p>, /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) 的股东在 2026 年 5 月 16 日披露其 fianlimab + Libtayo 的 III 期黑色素瘤试验未能达到主要终点后，股票大幅下跌，遭受了重大损失。投资者如果在 REGN 上亏损，鼓励您现在提交信息以讨论您的法律权利。您也可以通过电子邮件联系 Joseph E. Levi, Esq.，邮箱为 [email protected] 或拨打电话 (212) 363-7500。</p>
<p>在 2025 年 11 月和 12 月的医疗会议上，Regeneron 的高管积极强调其 LAG-3 研究的延迟，向投资者保证他们 “相信这是因为测试组表现良好。” Regeneron 投资者关系高级副总裁 Ryan Crowe 指出，这只是 “事件发生率的放缓”，同时向投资者确认管理层仍然 “对 fianlimab 加 Libtayo 能够在当前治疗标准中产生显著差异充满希望和信心。”</p>
<p>购买了 Regeneron 股票并遭受损失的股东被鼓励点击此处获取有关 REGN 调查的更多信息。您也可以通过电子邮件联系 Joseph E. Levi, Esq.，邮箱为 [email protected] 或拨打电话 (212) 363-7500。</p>
<p>Levi &amp; Korsinsky, LLP -- 前 50 大证券诉讼公司（ISS，连续七年）。超过 70 名专业人士。已追回数亿资金。</p>
<p>关于 REGN 调查的常见问题</p>
<p><strong>问：谁有资格参与 REGN 调查？</strong> 答：购买了 REGN 股票或证券并遭受财务损失的投资者可能有资格。资格基于购买日期和记录的损失，而不是您是否仍持有股票。</p>
<p><strong>问：哪些声明被调查为可能具有误导性？</strong> 答：调查涉及 Regeneron Pharmaceuticals 是否就其 III 期黑色素瘤试验的潜力和进展做出了实质性虚假或误导性陈述。当试验失败被揭露时，股价急剧下跌。</p>
<p><strong>问：REGN 投资者现在需要做什么？</strong> 答：收集经纪记录，包括购买日期、股票数量和支付价格。联系 Levi &amp; Korsinsky 进行免费的无义务评估，邮箱为 [email protected] 或拨打电话 (212) 363-7500。无需立即采取行动以保持参与调查的资格。</p>
<p><strong>问：我联系 Levi &amp; Korsinsky 后会发生什么？</strong> 答：律师将免费审查您的交易历史，并提供您潜在赔偿的初步评估。</p>
<p><strong>问：如果我已经出售了我的 REGN 股票 -- 我还可以追回损失吗？</strong> 答：可以。资格基于您购买的时间，而不是您是否仍持有股票。购买了 REGN 并以亏损出售的投资者仍然可以参与调查。</p>
<p><strong>问：我需要去法庭或作证吗？</strong> 答：不需要。参与调查不需要出庭或作证。如果后续采取法律行动，绝大多数受影响的投资者也不需要出庭。</p>
<p><strong>问：参与需要我支付什么费用吗？</strong> 答：不需要。证券调查及任何后续行动均以纯粹的风险代理方式进行。没有前期费用，没有保留金，没有自付费用。</p>
<p>联系方式：\</p>
<p>Levi &amp; Korsinsky, LLP\</p>
<p>Joseph E. Levi, Esq.\</p>
<p>Ed Korsinsky, Esq.\</p>
<p>33 Whitehall Street, 27th Floor\</p>
<p>New York, NY 10004\</p>
<p>[email protected]\</p>
<p>电话: (212) 363-7500\</p>
<p>传真: (212) 363-7171</p>
<p>来源 Levi &amp; Korsinsky, LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9Tlk2MjI1MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxODI0UFJfTkVXU19VU1BSX19fX19OWTYyMjUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9Tlk2MjI1MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxODI0UFJfTkVXU19VU1BSX19fX19OWTYyMjUw"/></p>

再生元制药

基因改革 ETF - ARK

医疗业 ETF - Vanguard

<p>Levi & Korsinsky 正在调查再生元制药（Regeneron Pharmaceuticals，REGN），因其在 fianlimab + Libtayo 的 III 期黑色素瘤试验失败后，股票遭遇重大损失。该股票在试验未能达到主要终点后下跌超过 10%。遭受损失的股东被鼓励联系该公司以寻求潜在的法律救济</p>

<p><em>Regeneron's executives were optimistic about the potential for fianlimab + Libtayo; when the study failed to produce exepected results, the stock opened down more than 10%.</em></p>
<div class="lb-trans"><p>Regeneron 的高管对 fianlimab + Libtayo 的潜力持乐观态度；当研究未能产生预期结果时，股票开盘下跌超过 10%。</p>
</div><p>, /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw significant losses when the stock dropped sharply following the May 16, 2026 disclosure that its Phase 3 melanoma trial of fianlimab + Libtayo failed to meet its primary endpoint versus Keytruda. Investors who lost money on REGN are encouraged to submit their information now to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) 的股东在 2026 年 5 月 16 日披露其 fianlimab + Libtayo 的 III 期黑色素瘤试验未能达到主要终点后，股票大幅下跌，遭受了重大损失。投资者如果在 REGN 上亏损，鼓励您现在提交信息以讨论您的法律权利。您也可以通过电子邮件联系 Joseph E. Levi, Esq.，邮箱为 [email protected] 或拨打电话 (212) 363-7500。</p>
</div><p>During healthcare conference presentations in November and December of 2025, Regeneron executives positively highlighted a delay to its LAG-3 study, assuring investors they &#34;believe this is because the test arms are performing well.&#34; Regeneron's Senior Vice President of Investor Relations, Ryan Crowe, noted it was just a mere &#34;slowing of event rates&#34; while confirming to investors management still had &#34;a lot of hope and confidence that fianlimab-plus Libtayo can generate a meaningful differentiation against current standards of care.&#34;</p>
<div class="lb-trans"><p>在 2025 年 11 月和 12 月的医疗会议上，Regeneron 的高管积极强调其 LAG-3 研究的延迟，向投资者保证他们 “相信这是因为测试组表现良好。” Regeneron 投资者关系高级副总裁 Ryan Crowe 指出，这只是 “事件发生率的放缓”，同时向投资者确认管理层仍然 “对 fianlimab 加 Libtayo 能够在当前治疗标准中产生显著差异充满希望和信心。”</p>
</div><p>Shareholders who purchased Regeneron stock and suffered a loss are encouraged to click here to get more information about the REGN investigation. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.</p>
<div class="lb-trans"><p>购买了 Regeneron 股票并遭受损失的股东被鼓励点击此处获取有关 REGN 调查的更多信息。您也可以通过电子邮件联系 Joseph E. Levi, Esq.，邮箱为 [email protected] 或拨打电话 (212) 363-7500。</p>
</div><p>Levi &amp; Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP -- 前 50 大证券诉讼公司（ISS，连续七年）。超过 70 名专业人士。已追回数亿资金。</p>
</div><p>Frequently Asked Questions About the REGN Investigation</p>
<div class="lb-trans"><p>关于 REGN 调查的常见问题</p>
</div><p><strong>Q: Who is eligible to participate in the REGN investigation?</strong> A: Investors who purchased REGN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.</p>
<div class="lb-trans"><p><strong>问：谁有资格参与 REGN 调查？</strong> 答：购买了 REGN 股票或证券并遭受财务损失的投资者可能有资格。资格基于购买日期和记录的损失，而不是您是否仍持有股票。</p>
</div><p><strong>Q: Which statements are being investigated as potentially misleading?</strong> A: The investigation concerns whether Regeneron Pharmaceuticals made materially false or misleading statements regarding the potential and progress of its Phase 3 melanoma trial. When the trial failure was revealed, the stock price declined sharply.</p>
<div class="lb-trans"><p><strong>问：哪些声明被调查为可能具有误导性？</strong> 答：调查涉及 Regeneron Pharmaceuticals 是否就其 III 期黑色素瘤试验的潜力和进展做出了实质性虚假或误导性陈述。当试验失败被揭露时，股价急剧下跌。</p>
</div><p><strong>Q: What do REGN investors need to do right now?</strong> A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi &amp; Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.</p>
<div class="lb-trans"><p><strong>问：REGN 投资者现在需要做什么？</strong> 答：收集经纪记录，包括购买日期、股票数量和支付价格。联系 Levi &amp; Korsinsky 进行免费的无义务评估，邮箱为 [email protected] 或拨打电话 (212) 363-7500。无需立即采取行动以保持参与调查的资格。</p>
</div><p><strong>Q: What happens after I contact Levi &amp; Korsinsky?</strong> A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.</p>
<div class="lb-trans"><p><strong>问：我联系 Levi &amp; Korsinsky 后会发生什么？</strong> 答：律师将免费审查您的交易历史，并提供您潜在赔偿的初步评估。</p>
</div><p><strong>Q: What if I already sold my REGN shares -- can I still recover losses?</strong> A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought REGN and sold at a loss may still participate in the investigation.</p>
<div class="lb-trans"><p><strong>问：如果我已经出售了我的 REGN 股票 -- 我还可以追回损失吗？</strong> 答：可以。资格基于您购买的时间，而不是您是否仍持有股票。购买了 REGN 并以亏损出售的投资者仍然可以参与调查。</p>
</div><p><strong>Q: Do I need to go to court or give testimony?</strong> A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.</p>
<div class="lb-trans"><p><strong>问：我需要去法庭或作证吗？</strong> 答：不需要。参与调查不需要出庭或作证。如果后续采取法律行动，绝大多数受影响的投资者也不需要出庭。</p>
</div><p><strong>Q: What does it cost me to participate?</strong> A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.</p>
<div class="lb-trans"><p><strong>问：参与需要我支付什么费用吗？</strong> 答：不需要。证券调查及任何后续行动均以纯粹的风险代理方式进行。没有前期费用，没有保留金，没有自付费用。</p>
</div><p>CONTACT:\</p>
<div class="lb-trans"><p>联系方式：\</p>
</div><p>Levi &amp; Korsinsky, LLP\</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP\</p>
</div><p>Joseph E. Levi, Esq.\</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.\</p>
</div><p>Ed Korsinsky, Esq.\</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.\</p>
</div><p>33 Whitehall Street, 27th Floor\</p>
<div class="lb-trans"><p>33 Whitehall Street, 27th Floor\</p>
</div><p>New York, NY 10004\</p>
<div class="lb-trans"><p>New York, NY 10004\</p>
</div><p>[email protected]\</p>
<div class="lb-trans"><p>[email protected]\</p>
</div><p>Tel: (212) 363-7500\</p>
<div class="lb-trans"><p>电话: (212) 363-7500\</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>传真: (212) 363-7171</p>
</div><p>SOURCE Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>来源 Levi &amp; Korsinsky, LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9Tlk2MjI1MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxODI0UFJfTkVXU19VU1BSX19fX19OWTYyMjUw" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY62250&amp;Transmission_Id=202605181824PR_NEWS_USPR_____NY62250&amp;DateId=20260518"/></p>

18:24 ETRegeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)

prnewswire

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

美国制药 ETF - iShares

标普生物技术 3 倍做多 - Direxion

标普生物技术 3 倍做空 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

Invesco Nasdaq Biotechnology ETF

18:24 ET 再生元制药调查启动：Levi & Korsinsky 对再生元制药（REGN）的高管和董事进行调查